^
Association details:
| Biomarker: | PIK3CA H1047L |
|---|---|
| Cancer: | Oral Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance
Excerpt:
We found that two out of three cell line in the resistant group carried mutations in PIK3CA (H1047L and Q546R in ORL-115 and ORL-150, respectively)12,18, while none of the palbociclib-sensitive cell lines had any mutations in this gene…
DOI:
10.20892/j.issn.2095-3941.2018.0257
